Research Analysts Set Expectations for DNTH FY2026 Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Cantor Fitzgerald issued their FY2026 earnings per share estimates for Dianthus Therapeutics in a report released on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will post earnings of ($3.44) per share for the year. The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($2.61) per share.

Several other analysts have also recently commented on DNTH. Guggenheim reiterated a "buy" rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Robert W. Baird dropped their price target on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th. Wedbush reissued an "outperform" rating and set a $36.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, HC Wainwright reissued a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $53.00.

Dianthus Therapeutics Stock Performance

Shares of DNTH traded down $0.63 during trading hours on Tuesday, hitting $18.12. 217,250 shares of the stock were exchanged, compared to its average volume of 278,827. Dianthus Therapeutics has a 12-month low of $13.37 and a 12-month high of $32.27. The company has a market cap of $582.74 million, a price-to-earnings ratio of -7.25 and a beta of 1.36. The stock's 50-day moving average price is $18.98 and its two-hundred day moving average price is $21.19.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $1.16 million during the quarter, compared to analysts' expectations of $0.81 million.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of hedge funds have recently modified their holdings of DNTH. US Bancorp DE boosted its holdings in Dianthus Therapeutics by 2,013.3% during the 1st quarter. US Bancorp DE now owns 1,585 shares of the company's stock valued at $29,000 after acquiring an additional 1,510 shares during the period. KLP Kapitalforvaltning AS purchased a new position in Dianthus Therapeutics during the 4th quarter valued at about $33,000. KBC Group NV purchased a new position in Dianthus Therapeutics during the 4th quarter valued at about $35,000. BNP Paribas Financial Markets purchased a new position in Dianthus Therapeutics during the 4th quarter valued at about $59,000. Finally, GAMMA Investing LLC boosted its holdings in Dianthus Therapeutics by 3,030.6% during the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock valued at $70,000 after acquiring an additional 3,758 shares during the period. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.